PMID: 6164476Apr 15, 1981Paper

Chemotherapy for head and neck cancer relapsing after radiotherapy

Cancer
E P CortesK Heller

Abstract

Thirty-nine patients (28 men and 11 women, ages 43 to 83 years) with advanced head and neck epidermoid carcinoma (33 had relapsed from previous radiotherapy) were treated with a three-day bleomycin administration (30 by continuous intravenous infusion and nine by subcutaneous route) followed on the fifth day by intravenous administration of cyclophosphamide + methotrexate + 5-fluorouracil (Bleo-CMF). This drug schedule was based on the cell cycle synchrony principle. Twenty-one of 39 patients (54%) responded (seven complete, 14 partial remission) lasting from 4 to 20 months. The median duration of survival for complete remission, partial remission, and disease progression was 15, ten, and four months, respectively. The Bleo-CMF was well tolerated with minimal toxicity. The effectiveness of this regimen in previously irradiated patients compels us to pursue its application in a randomized study as an adjuvant for Stages III and IV head and neck cancer following maximum eradication of the local disease by surgery and/or radiotherapy.

Citations

Jun 15, 1995·International Journal of Radiation Oncology, Biology, Physics·M AltunF Eschwege
Jul 1, 1987·International Journal of Radiation Oncology, Biology, Physics·J J MazeronF Feuilhade
Aug 1, 1986·Current Problems in Surgery·D G McQuarrie
Aug 1, 1989·Journal of Chemotherapy·M AiroldiV Brando

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

International Journal of Radiation Oncology, Biology, Physics
R G LaneI I Rosen
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J H SchornagelF Cognetti
© 2021 Meta ULC. All rights reserved